Selected Publications

(*shared authorship, **corresponding author)

 

Stein A*, Paschold L*, Tintelnot J, Gökkurt E, Henkes SS, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka  S, Al-Batran SA, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hegewisch-Becker S, Binder M. Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive Esophago Gastric Adenocarcinoma – the randomized AIO INTEGA trial.
JAMA oncology. JAMA Oncol. 2022 Jun 23. doi: 10.1001/jamaoncol.2022.2228. 
https://jamanetwork.com/journals/jamaoncology/fullarticle/2793712 

Schultheiß C*, Paschold L*, Simnica D*, Mohme M, Willscher E, von Wenserski L, Scholz R, Wieters I, Dahlke C, Tolosa E, Sedding DG, Ciesek S, Addo M, Binder M. Next Generation Sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease.
Immunity. 2020 Aug 18;53(2):442-455. doi: 10.1016/j.immuni.2020.06.024. 
https://www.sciencedirect.com/science/article/pii/S107476132030279X?via%3Dihub 

Stein A*, Simnica D*, Schultheiß C*, Scholz R, Tintelnot J, Goekkurt E, von Wenserski L, Willscher E, Paschold L, Sauer M, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich T, Doerfel S, Al-Batran SE, Karthaus, M, Pelzer U, Waberer L, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.
J Immunother Cancer. 2021 Jul;9(7):e002844. doi: 10.1136/jitc-2021-002844.
https://jitc.bmj.com/content/9/7/e002844 

Paschold L, Simnica D, Benitez Brito R, Zhang T, Schultheiß C, Dierks C, Binder M. Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21R110 chronic lymphocytic leukemia.
Blood Cancer J. 2022 Mar 30;12(3):49. doi: 10.1038/s41408-022-00650-4.
https://www.nature.com/articles/s41408-022-00650-4 

Paschold L*, Simnica D*, Willscher E, Vehreschild MJGT, Dutzmann J, Sedding DG, Schultheiß C, Binder  M. SARS-CoV-2 specific antibody rearrangements in pre-pandemic immune repertoires of risk cohorts and COVID-19 patients.
J Clin Invest. 2021 Jan 4;131(1):e142966. doi: 10.1172/JCI142966.

Paschold L, Stein A, Thiele B, Henkes SS, Coith C, Schultheiss C, Pantel K, Riethdorf S, Binder M. First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial.
J Immunother Cancer. 2023 Jun;11(6):e006678. doi: 10.1136/jitc-2023-006678.
https://jitc.bmj.com/content/11/6/e006678 

Porritt RA*, Paschold L*, Rivas MN, Cheng MH, Yonker LM, Chandnani H, Lopez M, Simnica S, Schultheiß C, Santiskulvong C, Van Eyk J, McCormick JK, Fasano A, Bahar I, Binder M**, Arditi M**. HLA Class I-associated expansion of TRBV11-2 T cells in Multisystem Inflammatory Syndrome in Children.
J Clin Invest. 2021 May 17;131(10):e146614. doi: 10.1172/JCI146614.
https://www.jci.org/articles/view/146614 

Schultheiß C, Simnica D, Willscher E, Oberle A, Fanchi LF, Bonzanni N, Wildner N, Schulze-Zur-Wiesch J, Weiler-Normann C, Lohse AW, Binder M. Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
Hepatology. 2021 Apr;73(4):1436-1448. doi: 10.1002/hep.31473.
https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.31473 

von Wenserski L, Schultheiß C, Bolz S, Schliffke S, Simnica D, Willscher E, Gerull H, Bobusch A-L, Riecken K, Fehse B, Altfeld M, Nollau P, Binder M. SLAMF receptors negatively regulate B cell rece­ptor signaling in chronic lymphocytic leukemia via prohibitin-2.
Leukemia. 2020. Apr;35(4):1073-1086. doi: /10.1038/s41375-020-01025-z.
https://www.nature.com/articles/s41375-020-01025-z 

Porritt RA, Binek A, Paschold L, Rivas MN, McArdle A, Yonker LM, Alter G, Chandnani HK, Lopez M, Fasano A, Van Eyk JE, Binder M, Arditi M. The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children.
J Clin Invest. 2021 Oct 15;131(20):e151520. doi: 10.1172/JCI151520.
https://www.jci.org/articles/view/151520 

Cheng MH, Zhang S, Porritt RA, Noval Rivas M, Paschold L, Willscher E, Binder M, Arditi M, Bahar I. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation.
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25254-25262. doi: 10.1073/pnas.2010722117.
https://www.pnas.org/doi/10.1073/pnas.2010722117 

Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab.
Blood. 2006 Sep 15;108(6):1975-8. doi: 10.1182/blood-2006-04-014639.
https://ashpublications.org/blood/article/108/6/1975/22609/The-epitope-recognized-by-rituximab 

Paschold L, Willscher E, Bein J, Vornanen M, Eichenauer DA, Simnica D, Thiele B, Wickenhauser C, Rosenwald A, Bernd HW, Klapper W, Feller AC, Ott G, Fend F, Hartmann S, Binder M. Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation.
Haematologica. 2021 Oct 1;106(10):2654-2666. doi: 10.3324/haematol.2021.278427.
https://haematologica.org/article/view/haematol.2021.278427